Policies and Procedures: Difference between revisions

No edit summary
No edit summary
Line 242: Line 242:
|07/20/90
|07/20/90
|12/09/20
|12/09/20
|12/09/20
|09/17/26
|-
|-
|[[Latex Sensitivity]]
|[[Latex Sensitivity]]
Line 414: Line 414:
|08/10/06
|08/10/06
|07/10/23
|07/10/23
|07/09/24
|09/17/26
|-
|-
|[[Inspections/Investigations by Third Parties]]
|[[Inspections/Investigations by Third Parties]]
Line 420: Line 420:
|10/16/04
|10/16/04
|01/20/23
|01/20/23
|07/09/24
|09/17/26
|-
|-
|[[Research Integrity]]
|[[Research Integrity]]
Line 426: Line 426:
|02/11/05
|02/11/05
|10/06/25
|10/06/25
|10/06/25
|09/17/26
|-
|-
|[[Export Control]]
|[[Export Control]]
Line 438: Line 438:
|03/13/09
|03/13/09
|07/09/24  
|07/09/24  
|07/09/24
|09/17/26
|-
|-
|[[Use of Human Anatomical Material]]
|[[Use of Human Anatomical Material]]
Line 444: Line 444:
|08/10/05
|08/10/05
|10/16/24
|10/16/24
|10/16/24
|09/17/26
|-
|-
|[[Clinical Research and Clinical Trial Professional and Technical Fee Billing]]
|[[Clinical Research and Clinical Trial Professional and Technical Fee Billing]]
Line 456: Line 456:
|11/01/06
|11/01/06
|07/09/24
|07/09/24
|07/09/24
|09/17/26
|-
|-
|[[Conflict of Interest]]
|[[Conflict of Interest]]
Line 468: Line 468:
|01/13/10
|01/13/10
|07/09/24
|07/09/24
|07/09/24
|09/17/26
|-
|-
|[[Principles of Financial Stewardship]]
|[[Principles of Financial Stewardship]]
Line 474: Line 474:
|08/01/10
|08/01/10
|07/21/23
|07/21/23
|07/09/24
|09/17/26
|-
|-
|[[Human Tissue Use and Transfer]]
|[[Human Tissue Use and Transfer]]
Line 498: Line 498:
|11/28/16
|11/28/16
|08/08/17
|08/08/17
|07/23/24
|09/17/26
|-
|-
|[[Whistleblower]]
|[[Whistleblower]]
Line 510: Line 510:
|08/14/23
|08/14/23
|09/13/23
|09/13/23
|07/09/24
|09/17/26
|-
|-
|[[UNMC AI Use Guidelines]]
|[[UNMC AI Use Guidelines]]